Abstract
To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (Abeta(1-42)), total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD dementias (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD dementias, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4pg/mL (acc=0.73), 52.8pg/mL (acc=0.73) and 35.3pg/mL (acc=0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD dementias was 50.4pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / diagnosis*
-
Amino Acid Sequence / physiology
-
Amyloid beta-Peptides / analysis
-
Amyloid beta-Peptides / cerebrospinal fluid
-
Autopsy
-
Biomarkers / analysis
-
Biomarkers / cerebrospinal fluid
-
Brain / metabolism
-
Brain / pathology
-
Brain / physiopathology
-
Catalytic Domain
-
Dementia / diagnosis*
-
Diagnosis, Differential
-
Female
-
Humans
-
Male
-
Neurofibrillary Tangles / metabolism
-
Neurofibrillary Tangles / pathology
-
Peptide Fragments / analysis
-
Peptide Fragments / cerebrospinal fluid
-
Phosphorylation
-
Plaque, Amyloid / metabolism
-
Predictive Value of Tests
-
Sensitivity and Specificity
-
Threonine / metabolism
-
tau Proteins / analysis
-
tau Proteins / cerebrospinal fluid*
-
tau Proteins / chemistry
Substances
-
Amyloid beta-Peptides
-
Biomarkers
-
MAPT protein, human
-
Peptide Fragments
-
amyloid beta-protein (1-42)
-
tau Proteins
-
Threonine